Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Go back to Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.11 | 52 Week High | $9.23 | |||
| Open | $10.11 | 52 Week Low | $1.16 | |||
| Day High | $10.11 | P/E | N/A | |||
| Day Low | $10.11 | EPS | $-0.30 | |||
| Volume | 4,436 | |||||
